Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer All Other Oncology — U.S. reported YoY by Quarter
All Other Oncology — U.S. reported YoY (%) (%)
Pfizer All Other Oncology — U.S. reported YoY: 27.0% in Q2 2026, up 5.0 pts from a year earlier.
Latest, Q2 2026
27.0%
Period ended Jun 28, 2026
Change on a year earlier
+5.0 pts
22.0% in Q2 2025
History
29 quarters
Since Q3 2018
Sources
29
Documents cited below
Where the Q2 2026 figure comes from
“|| All other Oncology | 338 | 394 | (14%) | (16%) | 178 | 141 | 27% | 159 | 253 | (37%) | (40%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer All Other Oncology — U.S. reported YoY (%), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/other-onc-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.